Cancer Research
Across the South East region, GLH staff work with oncology and clinical trials teams to assess whether patients are eligible for various genomics related cancer studies. For patients who have had genomic testing through the GLH as part of their cancer care, where appropriate, they will be identified for suitable clinical trials via our Genomic Tumour Advisory Board (GTAB) meetings and this will then be discussed with their oncologist.
For more information on cancer research within Guy’s and St Thomas’ NHS Foundation Trust and to contact the cancer research team, please visit the Guy’s Cancer Research webpage.
Examples of ongoing trials
Below are a few examples of the current early phase and late phase trails that are running in the region:
Main aims:
The ARROW clinical trial will test an investigational drug called pralsetinib (formerly known as BLU-667) in people who have RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or another solid tumor that has a RET fusion or mutation. It is a phase 1/2 trial designed to test the safety and the initial clinical activity of pralsetinib.
Inclusion criteria:
- At least 18 years of age
- Are not eligible for surgery and have exhausted all standard therapy options
- Have non-small cell lung cancer (NSCLC) with a known RET fusion or mutation OR
- Have medullary thyroid cancer (MTC) - a known RET alteration is not required OR
- Have another solid tumor with a known RET fusion or mutation.
Closing date: February 2024
Main aims:
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.
Inclusion criteria:
- At least 18 years of age
- Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1 that are considered nonamenable to surgery or other curative treatments or procedures
- Willingness to undergo a tumor biopsy to obtain tumor tissue
- Must have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to or ineligible for standard treatment.
Closing date: 12/08/2021
Main aims:
To assess the antitumor activity and safety of dostarlimab for patients with deficient mismatch repair endometrial cancer.
Inclusion criteria:
- At least 18 years of age
- Patients with deficient mismatch mutation repair endometrial cancer.
Closing date: 30/11/2023
Main aims:
The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer.
Inclusion criteria:
- At least 16 years of age
- Patients with a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT) OR
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.
Closing date: 31/03/2022
Main aims:
The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinations.
Inclusion criteria:
- At least 18 years of age
- Patients with non small cell lung cancer that is either squamous cell carcinoma or adenocarcinoma
- Histological or cytologically confirmed NSCLC stage III (not suitable for radical radiotherapy or surgery) or stage IV cancer
- Where one or more standard lines of treatment have failed and the cancer has continued to grow.
Closing date: September 2021